Two independent phase I trials of NK012, SN-38 incorporating micellar nanoparticle for patients with advanced cancer, opened in Japan and United States of America

Two independent phase I trials of NK012, SN-38 incorporating micellar nanoparticle for patients with advanced cancer, opened in Japan and United States of America

NK012 is a micellar drug that incorporates the CPT-11 active metabolite SN-38. Currently, CPT-11 is used for the treatment of a wide variety of cancer; however, it is expected that NK012 may show stronger antitumor effects of SN-38 than CPT-11. A phase I trial of NK012 was performed separately in th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug delivery system 2009, Vol.24 (1), p.54-61
Hauptverfasser: Horita, Yousuke, Hamaguchi, Tetsuya, Doi, Toshihiko, Takanashi, Masaya
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 61
container_issue 1
container_start_page 54
container_title Drug delivery system
container_volume 24
creator Horita, Yousuke
Hamaguchi, Tetsuya
Doi, Toshihiko
Takanashi, Masaya
description NK012 is a micellar drug that incorporates the CPT-11 active metabolite SN-38. Currently, CPT-11 is used for the treatment of a wide variety of cancer; however, it is expected that NK012 may show stronger antitumor effects of SN-38 than CPT-11. A phase I trial of NK012 was performed separately in the US and Japan, and the result of each trial showed that NK012 is well tolerated, suggesting its clinical usefulness.It is anticipated that the subsequent phase II and III trials will demonstrate the advantages of NK012 as a drug delivery system.
doi_str_mv 10.2745/dds.24.54
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20610408</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20610408</sourcerecordid><originalsourceid>FETCH-LOGICAL-c658-e46373a2efd39dd2b053242f538732ad87227abd5c6d5b754a11f23904d2be5c3</originalsourceid><addsrcrecordid>eNotkclOAzEMhiMEEmU58AY-ISExJevM9IgQS6GCA-U8cpMMDWqTIUlBvA5PSihcbNn-5N8LISeMjnkj1YUxaczlWMkdMmJtyyreCL5LRnTCRKUorffJQUpvlMpSZCPyPf8M4Lyxgy3GZxiWmCxMIUeHqwShh8cHyvg5PD9Woi2oDnEIEbPzr7B22q5WGMGjDwPG7PTKQh8iDAUo7RJ8urwENB_otTWgf108h1DkSug83OOAHtAbePEul9xzxmy3wpdrG53GI7LXl1Hs8b8_JPOb6_nVXTV7up1eXc4qXau2srIWjUBueyMmxvAFVYJL3ivRlgugaRvOG1wYpWujFo2SyFjPxYTKwlqlxSE5_Ws7xPC-sSl3a5e263kbNqnjtGZU0raAZ3-gjiGlaPtuiG6N8atjtPt9Qlee0HHZKSl-AC9-exk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20610408</pqid></control><display><type>article</type><title>Two independent phase I trials of NK012, SN-38 incorporating micellar nanoparticle for patients with advanced cancer, opened in Japan and United States of America</title><source>J-STAGE (Japan Science &amp; Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Horita, Yousuke ; Hamaguchi, Tetsuya ; Doi, Toshihiko ; Takanashi, Masaya</creator><creatorcontrib>Horita, Yousuke ; Hamaguchi, Tetsuya ; Doi, Toshihiko ; Takanashi, Masaya</creatorcontrib><description>NK012 is a micellar drug that incorporates the CPT-11 active metabolite SN-38. Currently, CPT-11 is used for the treatment of a wide variety of cancer; however, it is expected that NK012 may show stronger antitumor effects of SN-38 than CPT-11. A phase I trial of NK012 was performed separately in the US and Japan, and the result of each trial showed that NK012 is well tolerated, suggesting its clinical usefulness.It is anticipated that the subsequent phase II and III trials will demonstrate the advantages of NK012 as a drug delivery system.</description><identifier>ISSN: 0913-5006</identifier><identifier>EISSN: 1881-2732</identifier><identifier>DOI: 10.2745/dds.24.54</identifier><language>eng</language><ispartof>Drug delivery system, 2009, Vol.24 (1), p.54-61</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c658-e46373a2efd39dd2b053242f538732ad87227abd5c6d5b754a11f23904d2be5c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids></links><search><creatorcontrib>Horita, Yousuke</creatorcontrib><creatorcontrib>Hamaguchi, Tetsuya</creatorcontrib><creatorcontrib>Doi, Toshihiko</creatorcontrib><creatorcontrib>Takanashi, Masaya</creatorcontrib><title>Two independent phase I trials of NK012, SN-38 incorporating micellar nanoparticle for patients with advanced cancer, opened in Japan and United States of America</title><title>Drug delivery system</title><description>NK012 is a micellar drug that incorporates the CPT-11 active metabolite SN-38. Currently, CPT-11 is used for the treatment of a wide variety of cancer; however, it is expected that NK012 may show stronger antitumor effects of SN-38 than CPT-11. A phase I trial of NK012 was performed separately in the US and Japan, and the result of each trial showed that NK012 is well tolerated, suggesting its clinical usefulness.It is anticipated that the subsequent phase II and III trials will demonstrate the advantages of NK012 as a drug delivery system.</description><issn>0913-5006</issn><issn>1881-2732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNotkclOAzEMhiMEEmU58AY-ISExJevM9IgQS6GCA-U8cpMMDWqTIUlBvA5PSihcbNn-5N8LISeMjnkj1YUxaczlWMkdMmJtyyreCL5LRnTCRKUorffJQUpvlMpSZCPyPf8M4Lyxgy3GZxiWmCxMIUeHqwShh8cHyvg5PD9Woi2oDnEIEbPzr7B22q5WGMGjDwPG7PTKQh8iDAUo7RJ8urwENB_otTWgf108h1DkSug83OOAHtAbePEul9xzxmy3wpdrG53GI7LXl1Hs8b8_JPOb6_nVXTV7up1eXc4qXau2srIWjUBueyMmxvAFVYJL3ivRlgugaRvOG1wYpWujFo2SyFjPxYTKwlqlxSE5_Ws7xPC-sSl3a5e263kbNqnjtGZU0raAZ3-gjiGlaPtuiG6N8atjtPt9Qlee0HHZKSl-AC9-exk</recordid><startdate>2009</startdate><enddate>2009</enddate><creator>Horita, Yousuke</creator><creator>Hamaguchi, Tetsuya</creator><creator>Doi, Toshihiko</creator><creator>Takanashi, Masaya</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>2009</creationdate><title>Two independent phase I trials of NK012, SN-38 incorporating micellar nanoparticle for patients with advanced cancer, opened in Japan and United States of America</title><author>Horita, Yousuke ; Hamaguchi, Tetsuya ; Doi, Toshihiko ; Takanashi, Masaya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c658-e46373a2efd39dd2b053242f538732ad87227abd5c6d5b754a11f23904d2be5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Horita, Yousuke</creatorcontrib><creatorcontrib>Hamaguchi, Tetsuya</creatorcontrib><creatorcontrib>Doi, Toshihiko</creatorcontrib><creatorcontrib>Takanashi, Masaya</creatorcontrib><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Drug delivery system</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Horita, Yousuke</au><au>Hamaguchi, Tetsuya</au><au>Doi, Toshihiko</au><au>Takanashi, Masaya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two independent phase I trials of NK012, SN-38 incorporating micellar nanoparticle for patients with advanced cancer, opened in Japan and United States of America</atitle><jtitle>Drug delivery system</jtitle><date>2009</date><risdate>2009</risdate><volume>24</volume><issue>1</issue><spage>54</spage><epage>61</epage><pages>54-61</pages><issn>0913-5006</issn><eissn>1881-2732</eissn><abstract>NK012 is a micellar drug that incorporates the CPT-11 active metabolite SN-38. Currently, CPT-11 is used for the treatment of a wide variety of cancer; however, it is expected that NK012 may show stronger antitumor effects of SN-38 than CPT-11. A phase I trial of NK012 was performed separately in the US and Japan, and the result of each trial showed that NK012 is well tolerated, suggesting its clinical usefulness.It is anticipated that the subsequent phase II and III trials will demonstrate the advantages of NK012 as a drug delivery system.</abstract><doi>10.2745/dds.24.54</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0913-5006
ispartof Drug delivery system, 2009, Vol.24 (1), p.54-61
issn 0913-5006
1881-2732
language eng
recordid cdi_proquest_miscellaneous_20610408
source J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; EZB-FREE-00999 freely available EZB journals
title Two independent phase I trials of NK012, SN-38 incorporating micellar nanoparticle for patients with advanced cancer, opened in Japan and United States of America
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A05%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two%20independent%20phase%20I%20trials%20of%20NK012,%20SN-38%20incorporating%20micellar%20nanoparticle%20for%20patients%20with%20advanced%20cancer,%20opened%20in%20Japan%20and%20United%20States%20of%20America&rft.jtitle=Drug%20delivery%20system&rft.au=Horita,%20Yousuke&rft.date=2009&rft.volume=24&rft.issue=1&rft.spage=54&rft.epage=61&rft.pages=54-61&rft.issn=0913-5006&rft.eissn=1881-2732&rft_id=info:doi/10.2745/dds.24.54&rft_dat=%3Cproquest_cross%3E20610408%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20610408&rft_id=info:pmid/&rfr_iscdi=true